Saturday 17 October 2026 Export NVS’s income statement to Excel — free account

Novartis AG

NVS Healthcare Drug Manufacturers General

Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 17.4%, free cash flow fell 15.5% and total debt rose 52.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three, operating cash flow growth for three.

150.62 0.24 +0.16%

Follow NVS

Alert me

Market cap: $275.3B
P/E: 22.6×
Fwd P/E: 20.6×
Dividend yield: 3.15%
F-score: 8/9
Altman Z: 4.13
Beneish M: −2.49
Dividend safety: 66/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Novartis AG (NVS) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Novartis AG (NVS) trades at a P/E ratio of 22.6×. Over the past ten years it has ranged from 7.3× (September 2022) to 115× (January 2018); the current reading is higher than 59% of that period. That is below the Drug Manufacturers General industry median of 24.5× and in line with the Healthcare sector median of 23.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/NVS/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Novartis AG P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/NVS/metrics/pe-ratio">Novartis AG (NVS) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	19.1×	16.30%
FY2024	16.5×	17.21%
FY2023	14.0×	(51.40%)
FY2022	28.9×	254.26%
FY2021	8.2×	(69.33%)
FY2020	26.6×	43.55%
FY2019	18.5×	30.86%
FY2018	14.2×	(86.33%)
FY2017	104×	158.66%
FY2016	40.0×	283.87%

Period	P/E ratio	Change
Jun 2026	23.5×	8.14%
Mar 2026	21.8×	13.63%
Dec 2025	19.1×	9.90%
Sep 2025	17.4×	(0.65%)
42 more quarters	Free account

Against its own ten years

Low 7.3× High 115×

Ten-year median 20.5×

Current reading's percentile 56

Company	P/E ratio
GILD Gilead Sciences, Inc. compare	n/m
NVO Novo Nordisk A/S compare	9.5×
NVS Novartis AG	22.6×
AZN AstraZeneca PLC compare	24.5×
AMGN Amgen Inc. compare	26.7×
JNJ Johnson & Johnson compare	29.6×
PFE Pfizer Inc. compare	38.9×
ABBV AbbVie Inc. compare	80.6×
MRK Merck & Co., Inc. compare	117×
Drug Manufacturers General industry median	24.5×
Healthcare sector median	23.0×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Novartis AG (NVS) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on NVS

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on NVS

Stockrow Weekly